Cargando…
Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
Adriamycin (ADR) has been utilized to treat cancer for several decades. However, ADR-induced renal injury is one of the most common side effects accompanying ADR therapy. In the present study, we revealed that astragaloside IV (ASIV) was beneficial for renal injury caused by Adriamycin. We demonstra...
Autores principales: | Qin, Lu-Yun, Guan, Peng, Wang, Jian-Xin, Chen, Yu, Zhao, Ya-Shuo, Yang, Sheng-Chang, Guo, Ya-Jing, Wang, Na, Ji, En-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971812/ https://www.ncbi.nlm.nih.gov/pubmed/35370757 http://dx.doi.org/10.3389/fphar.2022.812594 |
Ejemplares similares
-
Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021) -
Astragaloside IV attenuates ferroptosis after subarachnoid hemorrhage via Nrf2/HO-1 signaling pathway
por: Liu, Zhuanghua, et al.
Publicado: (2022) -
Review on the protective mechanism of astragaloside IV against cardiovascular diseases
por: Yang, Chunkun, et al.
Publicado: (2023) -
Astragaloside IV, as a potential anticancer agent
por: Xia, Dongqin, et al.
Publicado: (2023) -
A Mechanistic Exploratory Study on the Therapeutic Efficacy of Astragaloside IV Against Diabetic Retinopathy Revealed by Network Pharmacology
por: Zhao, Zhi-Hao, et al.
Publicado: (2022)